Proteogenomic profiling uncovers differential therapeutic vulnerabilities between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic leukemia
Saved in:
Published in | Haematologica (Roma) Vol. 109; no. 7; pp. 2290 - 2296 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
Fondazione Ferrata Storti
01.07.2024
Ferrata Storti Foundation |
Subjects | |
Online Access | Get full text |
ISSN | 0390-6078 1592-8721 1592-8721 |
DOI | 10.3324/haematol.2023.283928 |
Cover
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 23 Disclosures Contributions LB, JB, MS, J-PB, AB, MR, OA and UF planned and directed the study. Patient-derived xenograft models were provided by BB, BM and J-PB. FB, JTD, VM, FD, DL and OA conducted proteomic profiling and analyzed proteomic data. DP provided bioinformatic analyses. LB designed and performed the in vitro experiments, supported by VJ, JS-D and RH. NQ generated dose-response curves. SB provided intellectual contributions to the project and to the interpretation of the results. LB, VJ and UF wrote the manuscript. Figures were designed and drafted by LB, DP, NQ, VJ, JS-D and UF. All authors edited and contributed to the final manuscript. No conflicts of interest to disclose. |
---|---|
ISSN: | 0390-6078 1592-8721 1592-8721 |
DOI: | 10.3324/haematol.2023.283928 |